Search

Your search keyword '"Nozawa, Masahiro"' showing total 509 results
Start Over Author "Nozawa, Masahiro"
509 results on '"Nozawa, Masahiro"'

1. Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial

Author

Shiota, Masaki, Miyake, Hideaki, Takahashi, Masayuki, Oya, Mototsugu, Tsuchiya, Norihiko, Masumori, Naoya, Matsuyama, Hideyasu, Obara, Wataru, Shinohara, Nobuo, Fujimoto, Kiyohide, Nozawa, Masahiro, Ohba, Kojiro, Ohyama, Chikara, Hashine, Katsuyoshi, Akamatsu, Shusuke, Kamba, Tomomi, Mita, Koji, Gotoh, Momokazu, Tatarano, Shuichi, Fujisawa, Masato, Tomita, Yoshihiko, Mukai, Shoichiro, Ito, Keiichi, Tanegashima, Tokiyoshi, Tokunaga, Shoji, and Eto, Masatoshi

Published
2023
Full Text
View/download PDF

3. A geometric analysis of nonlinear dynamics and its application to financial time series

Author

Shoji, Isao and Nozawa, Masahiro

Subjects
Quantitative Finance - Statistical Finance, Nonlinear Sciences - Chaotic Dynamics
Abstract

A geometric method to analyze nonlinear oscillations is discussed. We consider a nonlinear oscillation modeled by a second order ordinary differential equation without specifying the function form. By transforming the differential equation into the system of first order ordinary differential equations, the trajectory is embedded in $R^3$ as a curve, and thereby the time evolution of the original state can be translated into the behavior of the curve in $R^3$, or the vector field along the curve. We analyze the vector field to investigate the dynamic properties of a nonlinear oscillation. While the function form of the model is unspecified, the vector fields and those associated quantities can be estimated by a nonparametric filtering method. We apply the proposed analysis to the time series of the Japanese stock price index. The application shows that the vector field and its derivative will be used as the tools of picking up various signals that help understanding of the dynamic properties of the stock price index.

Published
2020

10. A multicenter retrospective study of nivolumab monotherapy in previously treated metastatic renal cell carcinoma patients: interim analysis of Japanese real-world data

Author

Hinata, Nobuyuki, Yonese, Junji, Masui, Satoru, Nakai, Yasutomo, Shirotake, Suguru, Tatsugami, Katsunori, Inamoto, Teruo, Nozawa, Masahiro, Ueda, Kosuke, Etsunaga, Toru, Osawa, Takahiro, Uemura, Motohide, Kimura, Go, Numakura, Kazuyuki, Yamana, Kazutoshi, Miyake, Hideaki, Fukasawa, Satoshi, Ochi, Kenya, Kaneko, Hirokazu, and Uemura, Hirotsugu

Published
2020
Full Text
View/download PDF

13. Disseminated intravascular coagulation induced by pazopanib following combination therapy of nivolumab plus ipilimumab in a patient with metastatic renal cell carcinoma

Author

Hashimoto, Mamoru, Nakayama, Takahito, Fujimoto, Saizo, Inoguchi, Shunsuke, Nishimoto, Mitsuhisa, Kikuchi, Takashi, Adomi, Shogo, Banno, Eri, De Velasco, Marco A., Saito, Yoshitaka, Shimizu, Nobutaka, Mori, Yasunori, Minami, Takafumi, Fujita, Kazutoshi, Nozawa, Masahiro, Nose, Kazuhiro, Yoshimura, Kazuhiro, and Uemura, Hirotsugu

Published
2022
Full Text
View/download PDF

14. Real‐world outcomes of avelumab plus axitinib as first‐line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J‐DART)

Author

Kato, Taigo, primary, Nakano, Yuzo, additional, Hongo, Fumiya, additional, Katano, Hidenori, additional, Miyagawa, Tomoaki, additional, Ueda, Kosuke, additional, Azuma, Haruhito, additional, Nozawa, Masahiro, additional, Hinata, Nobuyuki, additional, Hori, Junichi, additional, Otoshi, Taiyo, additional, Shimizu, Nobuaki, additional, Aizawa, Mana, additional, Osada, Shingo, additional, Matsui, Akiko, additional, Oya, Mototsugu, additional, Eto, Masatoshi, additional, Tomita, Yoshihiko, additional, Shinohara, Nobuo, additional, and Uemura, Hirotsugu, additional

Published
2023
Full Text
View/download PDF

18. Real‐world outcomes of avelumab plus axitinib as first‐line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J‐DART).

Author

Kato, Taigo, Nakano, Yuzo, Hongo, Fumiya, Katano, Hidenori, Miyagawa, Tomoaki, Ueda, Kosuke, Azuma, Haruhito, Nozawa, Masahiro, Hinata, Nobuyuki, Hori, Junichi, Otoshi, Taiyo, Shimizu, Nobuaki, Aizawa, Mana, Osada, Shingo, Matsui, Akiko, Oya, Mototsugu, Eto, Masatoshi, Tomita, Yoshihiko, Shinohara, Nobuo, and Uemura, Hirotsugu

Subjects
RENAL cell carcinoma, DRUG side effects, TERMINATION of treatment, JAPANESE people, SCIENTIFIC observation
Abstract

Objectives: In the phase 3 JAVELIN Renal 101 trial in patients with advanced renal cell carcinoma (aRCC), objective response rate (ORR) and progression‐free survival (PFS) were significantly improved in patients treated with first‐line avelumab plus axitinib vs sunitinib. Here we evaluate real‐world outcomes with first‐line avelumab plus axitinib in Japanese patients with aRCC. Methods: In this multicenter, noninterventional, retrospective study, clinical data from patients with aRCC treated with first‐line avelumab plus axitinib between December 2019 and December 2020 in Japan were reviewed. Endpoints included ORR and PFS per investigator assessment, and time to treatment discontinuation (TTD). Results: Data from 48 patients (median age, 69 years) from 12 sites were analyzed. Median follow‐up was 10.4 months (range, 2.6–16.5), and median duration of treatment was 7.4 months (range, 0.5–16.5). International Metastatic RCC Database Consortium risk category was favorable, intermediate, or poor in 16.7%, 54.2%, and 29.2% of patients, respectively. The ORR was 48.8% (95% CI, 33.3%–64.5%), including complete response in 3/43 patients (7.0%). Thirteen patients (27.1%) had disease progression or died, and median PFS was 15.3 months (95% CI, 9.7 months – not estimable). At data cutoff, 24 patients (50.0%) were still receiving avelumab plus axitinib, and median TTD was 15.2 months (95% CI, 7.4 months – not estimable). Three patients (6.3%) received high‐dose corticosteroid treatment for immune‐related adverse events, and 8 (16.7%) received treatment for infusion‐related reactions. Conclusions: We report the first real‐world evidence of the effectiveness and tolerability of first‐line avelumab plus axitinib in Japanese patients with aRCC. Results were comparable with the JAVELIN Renal 101 trial. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Japanese Expert Panel Meeting on the Management of Prostate Cancer with Bone Metastases

Author

Takahashi, Shunji, Kinuya, Seigo, Nonomura, Norio, Shinohara, Nobuo, Suzuki, Kazuhiro, Suzuki, Hiroyoshi, Nakamura, Katsumasa, Satoh, Takefumi, Tateishi, Ukihide, Yoneda, Toshiyuki, Horikoshi, Hiroyuki, Igawa, Tsukasa, Kamai, Takao, Koizumi, Mitsuru, Kosaka, Takeo, Matsubara, Nobuaki, Miyake, Hideaki, Mizokami, Atsushi, Mizowaki, Takashi, Nakamura, Naoki, Nozawa, Masahiro, Takahashi, Takeo, Uemura, Hiroji, Uemura, Motohide, Yokomizo, Akira, Yoshimura, Mana, and Kakehi, Yoshiyuki

Published
2018
Full Text
View/download PDF

20. Prognosis of Patients Receiving Chemotherapy for Metastatic Upper Tract Urothelial Carcinoma Compared With Metastatic Urinary Bladder Cancer

Author

ADOMI, SHOGO, primary, FUJITA, KAZUTOSHI, additional, KITA, HIROYUKI, additional, KUWAHARA, KEN, additional, AKASHI, YASUNORI, additional, NISHIMOTO, MITSUHISA, additional, MATSUMURA, NAOKI, additional, SUGIMOTO, KOICHI, additional, MINAMI, TAKAFUMI, additional, NOZAWA, MASAHIRO, additional, YOSHIMURA, KAZUHIRO, additional, TAHARA, HIDEO, additional, HIRAYAMA, AKIHIDE, additional, NISHIOKA, TSUKASA, additional, ESA, ATSUNOBU, additional, and UEMURA, HIROTSUGU, additional

Published
2023
Full Text
View/download PDF

21. Real‐world effectiveness of nivolumab and subsequent therapy in Japanese patients with metastatic renal cell carcinoma (POST‐NIVO study): 36‐month follow‐up results of a clinical chart review

Author

Yonese, Junji, primary, Hinata, Nobuyuki, additional, Masui, Satoru, additional, Nakai, Yasutomo, additional, Shirotake, Suguru, additional, Takeuchi, Ario, additional, Inamoto, Teruo, additional, Nozawa, Masahiro, additional, Ueda, Kosuke, additional, Etsunaga, Toru, additional, Osawa, Takahiro, additional, Uemura, Motohide, additional, Kimura, Go, additional, Numakura, Kazuyuki, additional, Yamana, Kazutoshi, additional, Miyake, Hideaki, additional, Fukasawa, Satoshi, additional, Morishima, Naoto, additional, Ito, Hiroaki, additional, and Uemura, Hirotsugu, additional

Published
2023
Full Text
View/download PDF

22. Prognosis of Patients Receiving Chemotherapy for Metastatic Upper Tract Urothelial Carcinoma Compared With Metastatic Urinary Bladder Cancer

Author

ADOMI, SHOGO, FUJITA, KAZUTOSHI, KITA, HIROYUKI, KUWAHARA, KEN, AKASHI, YASUNORI, NISHIMOTO, MITSUHISA, MATSUMURA, NAOKI, SUGIMOTO, KOICHI, MINAMI, TAKAFUMI, NOZAWA, MASAHIRO, YOSHIMURA, KAZUHIRO, TAHARA, HIDEO, HIRAYAMA, AKIHIDE, NISHIOKA, TSUKASA, ESA, ATSUNOBU, and UEMURA, HIROTSUGU

Subjects
Research Article
Abstract

Background/Aim: The treatment strategy for metastatic upper tract urothelial carcinoma (mUTUC) is currently based on the evidence from metastatic urinary bladder cancer (mUBC). However, some reports have shown that the outcomes of UTUC differ from those of UBC. Therefore, we retrospectively analyzed the prognosis of patients with mUBC and mUTUC treated with first-line platinum-based chemotherapy. Patients and Methods: Patients who underwent platinum-based chemotherapy at the Kindai University Hospital and affiliated hospitals between January 2010 and December 2021 were included in the study. There were 56 patients with mUBC and 73 with mUTUC. Kaplan–Meier curves were used to estimate progression-free (PFS) and overall (OS) survival. Multivariate analyses were performed using Cox proportional hazards model to predict prognostic factors. Results: The median PFS was 4.5 and 4.0 months for the mUBC and mUTUC groups, respectively (p=0.094). The median OS was 17.0 months for both groups (p=0.821). The multivariate analysis showed no prognostic factor for PFS. The multivariate analysis for OS showed that younger age at the initiation of chemotherapy and immune checkpoint inhibitor use after first-line therapy were significantly associated with better OS. Conclusion: Platinum-based chemotherapy had a similar effect on patients with mUTUC and mUBC.

Published
2023

28. Correction to: The development and validation of a “5A” severity scale for predicting in-hospital mortality after accidental hypothermia from J-point registry data

Author

Okada, Yohei, Matsuyama, Tasuku, Morita, Sachiko, Ehara, Naoki, Miyamae, Nobuhiro, Jo, Takaaki, Sumida, Yasuyuki, Okada, Nobunaga, Watanabe, Makoto, Nozawa, Masahiro, Tsuruoka, Ayumu, Fujimoto, Yoshihiro, Okumura, Yoshiki, Kitamura, Tetsuhisa, Yamamoto, Shungo, Iiduka, Ryoji, and Koike, Kaoru

Published
2019
Full Text
View/download PDF

29. The development and validation of a “5A” severity scale for predicting in-hospital mortality after accidental hypothermia from J-point registry data

Author

Okada, Yohei, Matsuyama, Tasuku, Morita, Sachiko, Ehara, Naoki, Miyamae, Nobuhiro, Jo, Takaaki, Sumida, Yasuyuki, Okada, Nobunaga, Watanabe, Makoto, Nozawa, Masahiro, Tsuruoka, Ayumu, Fujimoto, Yoshihiro, Okumura, Yoshiki, Kitamura, Tetsuhisa, Yamamoto, Shungo, Iiduka, Ryoji, and Koike, Kaoru

Published
2019
Full Text
View/download PDF

32. Abstract 3044: Integrative gut microbiome analysis of human and mouse prostate cancer

Author

Wakamori, Chisato, primary, De Velasco, Marco A., additional, Kura, Yurie, additional, Ando, Naomi, additional, Sako, Noriko, additional, Fujita, Kazutoshi, additional, Sakai, Kazuko, additional, Matsushita, Makoto, additional, Banno, Eri, additional, Mori, Yasunori, additional, Nozawa, Masahiro, additional, Nishimoto, Mitsuhisa, additional, Yoshimura, Kazuhiro, additional, Nonomura, Norio, additional, Nishio, Kazuto, additional, and Uemura, Hirotsugu, additional

Published
2023
Full Text
View/download PDF

33. Abstract 2877: Profiling of myeloid-derived suppressor cells in Pten-deficient in prostate cancer progression

Author

De Velasco, Marco A., primary, Kura, Yurie, additional, Sako, Noriko, additional, Ando, Naomi, additional, Sakai, Kazuko, additional, Banno, Eri, additional, Adomi, Shogo, additional, Nishimoto, Mitsuhisa, additional, Minami, Takafumi, additional, Mori, Yasunori, additional, Fujita, Kazutoshi, additional, Nozawa, Masahiro Nozawa, additional, Yoshimura, Kazuhiro, additional, Nishio, Kazuto, additional, and Uemura, Hirotsugu, additional

Published
2023
Full Text
View/download PDF

34. Abstract 640: Exploring the relationships between prostate cancer, colorectal cancer, and ulcerative colitis

Author

De Velasco, Marco A., primary, Kura, Yurie, additional, Sakai, Kazuko, additional, Ando, Naomi, additional, Sako, Noriko, additional, Fujita, Kazutoshi, additional, Adomi, Shogo, additional, Banno, Eri, additional, Mori, Yasunori, additional, Minami, Takafumi, additional, Nozawa, Masahiro, additional, Yoshimura, Kazuhiro, additional, Nishio, Kazuto, additional, and Uemura, Hirotsugu, additional

Published
2023
Full Text
View/download PDF

35. Abstract 5155: Targeting tumor infiltrating myeloid cells in prostate cancer

Author

De Velasco, Marco A., primary, Kura, Yurie, additional, Ando, Naomi, additional, Sako, Noriko, additional, Fujita, Kazutoshi, additional, Sakai, Kazuko, additional, Schuller, Alwin G., additional, Sachsenmeier, Kris F., additional, Nozawa, Masahiro, additional, Banno, Eri, additional, Yoshimura, Kazuhiro, additional, Nishio, Kazuto, additional, and Uemura, Hirotsugu, additional

Published
2023
Full Text
View/download PDF

39. Immunohistochemical Analysis of HER2, EGFR, and Nectin-4 Expression in Upper Urinary Tract Urothelial Carcinoma

Author

HASHIMOTO, MAMORU, primary, FUJITA, KAZUTOSHI, additional, TOMIYAMA, EISUKE, additional, FUJIMOTO, SAIZO, additional, ADOMI, SHOGO, additional, BANNO, ERI, additional, MINAMI, TAKAFUMI, additional, TAKAO, TETSUYA, additional, NOZAWA, MASAHIRO, additional, FUSHIMI, HIROAKI, additional, YOSHIMURA, KAZUHIRO, additional, NONOMURA, NORIO, additional, and UEMURA, HIROTSUGU, additional

Published
2022
Full Text
View/download PDF

40. Prognostic value of PD-L1 expression in recurrent renal cell carcinoma after nephrectomy: a secondary analysis of the ARCHERY study

Author

Tamada, Satoshi, primary, Nozawa, Masahiro, additional, Ohba, Kojiro, additional, Mizuno, Ryuichi, additional, Takamoto, Atsushi, additional, Ohe, Chisato, additional, Yoshimoto, Takuya, additional, Nakagawa, Yuki, additional, Fukuyama, Tamaki, additional, Matsubara, Nobuaki, additional, Kimura, Go, additional, Tomita, Yoshihiko, additional, Nonomura, Norio, additional, and Eto, Masatoshi, additional

Published
2022
Full Text
View/download PDF

41. Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study

Author

Eto, Masatoshi, primary, Takagi, Toshio, additional, Kimura, Go, additional, Fukasawa, Satoshi, additional, Tamada, Satoshi, additional, Miura, Yuji, additional, Oya, Mototsugu, additional, Sassa, Naoto, additional, Anai, Satoshi, additional, Nozawa, Masahiro, additional, Sakai, Hideki, additional, Perini, Rodolfo, additional, Yusa, Wataru, additional, Ikezawa, Hiroki, additional, Narita, Tomoyuki, additional, and Tomita, Yoshihiko, additional

Published
2022
Full Text
View/download PDF

43. Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiP‐RCC study.

Author

Blas, Leandro, Shiota, Masaki, Miyake, Hideaki, Takahashi, Masayuki, Oya, Mototsugu, Tsuchiya, Norihiko, Masumori, Naoya, Matsuyama, Hideyasu, Obara, Wataru, Shinohara, Nobuo, Fujimoto, Kiyohide, Nozawa, Masahiro, Ohba, Kojiro, Ohyama, Chikara, Hashine, Katsuyoshi, Akamatsu, Shusuke, Kamba, Tomomi, Mita, Koji, Gotoh, Momokazu, and Tatarano, Shuichi

Subjects
NIVOLUMAB, KARNOFSKY Performance Status, PROGNOSIS, JAPANESE people, PROGRESSION-free survival, RENAL cell carcinoma
Abstract

Background: This study is part of the SNPs in Nivolumab PD‐1 inhibitor for RCC (SNiP‐RCC). Here we aimed to reveal clinical factors for tumor response, progression, and survival in nivolumab for advanced clear cell renal cell carcinoma (RCC) in Japanese patients. Methods: We included patients from 23 institutions in Japan. We evaluated the objective response, radiographic progression‐free survival (PFS), overall survival (OS), and treatment‐related grade ≥ 3 (serious adverse events [SAEs]). Results: We included 222 patients. The median age was 69 years (interquartile range 62–74 years), and 71% of the patients were male. Pancreas metastasis, lung metastases, prior cytokine therapy, and SAEs, were associated with objective response. The median PFS was 18 months. Liver metastases (hazard ratio [HR], 1.61), age ≥ 75 (HR, 0.48), previous resection of primary sites (HR, 0.47), and SAEs (HR, 0.47) were independent prognostic factors for PFS. Karnofsky Performance Status <70 (HR, 2.90), high platelets (HR, 4.48), previous resection of primary sites (HR, 0.23), and pathological grade (HR, 0.19 for grade 2 and HR, 0.12 for grade 3) were independent prognostic factors for OS. SAEs were reported in 45 (20.3%) cases. In the group of patients with prior nephrectomy, SAEs were associated with objective response, PFS, and OS. Conclusion: The SNiP‐RCC study identified clinical parameters correlated with treatment outcomes in Japanese patients with priorly treated advanced clear cell RCC undergoing nivolumab monotherapy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

45. Sequential therapy with darolutamide in patients with non‐metastatic castration‐resistant prostate cancer resistant to enzalutamide or apalutamide

Author

Fujmoto, Saizo, primary, Fujita, Kazutoshi, additional, Nishimoto, Mitsuhisa, additional, Hamaguchi, Mamoru, additional, Kuwahara, Ken, additional, Hashimoto, Mamoru, additional, Adomi, Shogo, additional, Minami, Takafumi, additional, Nozawa, Masahiro, additional, Yoshimura, Kazuhiro, additional, and Uemura, Hirotsugu, additional

Published
2022
Full Text
View/download PDF

46. Prognostic factors in Japanese men with high-Gleason metastatic castration-resistant prostate cancer

Author

Nishimoto, Mitsuhisa, primary, Fujita, Kazutoshi, additional, Yamamoto, Yutaka, additional, Hashimoto, Mamoru, additional, Adomi, Shogo, additional, Banno, Eri, additional, Saito, Yoshitaka, additional, Shimizu, Nobutaka, additional, Mori, Yasunori, additional, Minami, Takafumi, additional, Nozawa, Masahiro, additional, Nose, Kazuhiro, additional, Hirayama, Akihide, additional, Yoshimura, Kazuhiro, additional, and Uemura, Hirotsugu, additional

Published
2022
Full Text
View/download PDF

47. Gas-Producing Splenic Abscess after Spleen Metastasis of Left Renal Cell Carcinoma Spleen Metastasis Successfully Treated with Sunitinib

Author

Kunishige, Remon, Ozeki, Takayuki, Hamaguchi, Mamoru, Toyoda, Shingo, Hashimoto, Mamoru, Kikuchi, Takashi, Nishimoto, Mitsuhisa, Shimizu, Nobutaka, Mori, Yasunori, Minami, Takafumi, Nozawa, Masahiro, Nose, Kazuhiro, Yoshimura, Kazuhiro, and Uemura, Hirotsugu

Subjects
Gas-producing splenic abscess, Renal cell carcinoma spleen metastasis, 494.9
Abstract

A 67-year-old man underwent open radical left nephrectomy for left renal cell carcinoma [pT4N0M1 (right lower lobe of lung)] and thoracoscopic partial right lung resection for lung metastasis. The patient subsequently developed a solitary lung metastasis at 10 months and then at 26 months postoperatively. He underwent partial lung resection on each occasion. During the 28 months postoperatively, he was found to have a 12 mm middle mediastinal lymph node metastasis and a 30 mm splenic metastasis, which gradually increased in size. Three months after discovery, sunitinib was initiated at 37.5 mg 2 weeks on/1 week off. Twelve days later, the patient presented with complaints of fever. A gas-producing splenic abscess was diagnosed and he was admitted on the same day. His condition improved with antibiotics and splenic drainage. On day 35 of hospitalization, he underwent laparoscopic splenectomy. The patient's postoperative clinical course was uneventful and he was discharged 7 days after the surgery.

Published
2021

49. Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer

Author

Nozawa, Masahiro, Mukai, Hirofumi, Takahashi, Shunji, Uemura, Hiroji, Kosaka, Takeo, Onozawa, Yusuke, Miyazaki, Jun, Suzuki, Kazuhiro, Okihara, Koji, Arai, Yoichi, Kamba, Tomomi, Kato, Masashi, Nakai, Yasutomo, Furuse, Hiroshi, Kume, Haruki, Ide, Hisamitsu, Kitamura, Hiroshi, Yokomizo, Akira, Kimura, Takahiro, Tomita, Yoshihiko, Ohno, Keiji, and Kakehi, Yoshiyuki

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results